TOT BIOPHARM International Co. Ltd. (HK:1875)
:1875
Want to see HK:1875 full AI Analyst Report?
1875 Stock Chart & Stats
HK$2.50
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$2.50
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$1.70 - HK$5.87
Previous CloseN/A
Volume400.00
Average Volume (3M)240.51K
Market Cap
HK$2.88B
Enterprise ValueHK$2.65B
Total Cash (Recent Filing)HK$328.47M
Total Debt (Recent Filing)HK$383.72M
Price to Earnings (P/E)―
Beta0.44
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding772,787,900
10 Day Avg. Volume141,880
30 Day Avg. Volume240,506
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.60
Price to Sales (P/S)2.18
P/FCF Ratio-60.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.18
Revenue Forecast (FY)HK$1.61B
Bulls Say, Bears Say
Bulls Say
CDMO/CMO And GMP Manufacturing CapabilitiesA diversified business model combining proprietary oncology drugs with contract development and GMP manufacturing creates multiple durable revenue streams. CDMO/CMO capabilities reduce reliance on single-product sales, support margin stability over time, and deepen partner relationships that can generate recurring service income.
Manageable Leverage And Balance Sheet StabilityA moderate debt profile provides financial flexibility to fund R&D and manufacturing investments without excessive refinancing risk. This steadier capital structure supports continued operations through cyclical revenue swings and underpins the company’s ability to pursue strategic partnerships or commercial scale-ups.
Historical Revenue Growth And Healthy Gross Margin BasePrior multi-year revenue expansion and generally healthy gross margins indicate underlying product and manufacturing economics. If management stabilizes demand, the existing margin base allows operating leverage to return, enabling profitability recovery without needing structural cost re-engineering.
Bears Say
Sharp Revenue Decline And Return To Losses In 2025A large, abrupt drop in revenue paired with reversion to net losses highlights demand, pricing or product-mix vulnerabilities. Such earnings volatility can impair long-term investment capacity, strain R&D timelines, and complicate sustaining commercial and manufacturing scale without clear recovery drivers.
Persistently Negative Free Cash Flow And Weaker 2025 Operating Cash FlowChronic negative free cash flow signals structural reinvestment needs or poor conversion of revenue into cash, limiting ability to self-fund growth and increasing reliance on external capital. Weakening operating cash flow in 2025 reduces buffer for R&D and capex, pressuring long-term sustainability.
Earnings Volatility And Negative ROE In 2025Volatile returns on equity undermine investor confidence and suggest inconsistent capital efficiency. Negative ROE indicates the company is not generating adequate returns on shareholders’ capital, complicating long-term funding, strategic planning, and ability to attract partners or favorable financing.
TOT BIOPHARM International Co. Ltd. News
1875 FAQ
What was TOT BIOPHARM International Co. Ltd.’s price range in the past 12 months?
TOT BIOPHARM International Co. Ltd. lowest stock price was HK$1.70 and its highest was HK$5.87 in the past 12 months.
What is TOT BIOPHARM International Co. Ltd.’s market cap?
TOT BIOPHARM International Co. Ltd.’s market cap is HK$2.88B.
When is TOT BIOPHARM International Co. Ltd.’s upcoming earnings report date?
TOT BIOPHARM International Co. Ltd.’s upcoming earnings report date is Aug 18, 2026 which is in 73 days.
How were TOT BIOPHARM International Co. Ltd.’s earnings last quarter?
TOT BIOPHARM International Co. Ltd. released its earnings results on Mar 18, 2026. The company reported -HK$0.158 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.158.
Is TOT BIOPHARM International Co. Ltd. overvalued?
According to Wall Street analysts TOT BIOPHARM International Co. Ltd.’s price is currently Overvalued.
Does TOT BIOPHARM International Co. Ltd. pay dividends?
TOT BIOPHARM International Co. Ltd. does not currently pay dividends.
What is TOT BIOPHARM International Co. Ltd.’s EPS estimate?
TOT BIOPHARM International Co. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TOT BIOPHARM International Co. Ltd. have?
TOT BIOPHARM International Co. Ltd. has 772,787,900 shares outstanding.
What happened to TOT BIOPHARM International Co. Ltd.’s price movement after its last earnings report?
TOT BIOPHARM International Co. Ltd. reported an EPS of -HK$0.158 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.695%.
Which hedge fund is a major shareholder of TOT BIOPHARM International Co. Ltd.?
Currently, no hedge funds are holding shares in HK:1875
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TOT BIOPHARM International Co. Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.06%
12-Months-Change
Fundamentals
Return on Equity
-14.78%
Trailing 12-Months
Asset Growth
-12.65%
Trailing 12-Months
Company Description
TOT BIOPHARM International Co. Ltd.
BioDlink International Co., Ltd. is clinical stage biopharmaceutical company, which engages in developing and commercializing oncology drugs and therapies. Its product portfolio includes: TAB008, TOZ309, TAA013, TAE020, TAB 014, and TAC020. The company was founded on December 4, 2009 and is headquartered in Suzhou, China.
Technical Analysis
Alphamab Oncology
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Lepu Biopharma Co. Ltd. Class H
―
CARsgen Therapeutics Holdings Ltd.
―
Shanghai Henlius Biotech, Inc. Class H
―